CDH Investments to acquire Sirtex for USD1.4bn
Law firm Paul Hastings has advised CDH Genetech (CDH), part of the CDH Investments group, on its agreement to acquire Australian-based medical device company Sirtex Medical (Sirtex) for AUD33.60 per share in cash through a Scheme of Arrangement. CDH is transacting the deal in conjunction with Hong Kong-listed China Grand